JPMorgan Chase & Co. Reiterates GBX 1400 Price Target for GSK … – MarketBeat

Written by Amanda

GSK (LON:GSKGet Rating) has been given a GBX 1,400 ($17.19) target price by stock analysts at JPMorgan Chase & Co. in a report released on Friday, Borsen Zeitung reports. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 0.03% from the company’s previous close.

→ “Prepare for Five Years of Famine” (From Legacy Research)

Other equities analysts have also issued reports about the company. Citigroup dropped their price objective on GSK from GBX 1,975 ($24.25) to GBX 1,550 ($19.03) and set a “neutral” rating on the stock in a research note on Friday, December 2nd. Barclays restated an “equal weight” rating and set a GBX 1,450 ($17.81) price objective on shares of GSK in a research report on Thursday, February 2nd. Jefferies Financial Group set a GBX 1,575 ($19.34) target price on GSK in a research report on Wednesday, February 1st. Shore Capital reissued a “buy” rating on shares of GSK in a report on Friday, February 24th. Finally, Deutsche Bank Aktiengesellschaft set a GBX 1,700 ($20.88) price objective on shares of GSK in a report on Monday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of GBX 1,573.33 ($19.32).

GSK Stock Performance

GSK stock traded down GBX 38.20 ($0.47) during trading hours on Friday, reaching GBX 1,399.60 ($17.19). 7,097,366 shares of the company were exchanged, compared to its average volume of 8,405,959. GSK has a 12 month low of GBX 1,280.92 ($15.73) and a 12 month high of GBX 2,280.50 ($28.01). The firm has a market cap of £57.24 billion, a price-to-earnings ratio of 1,260.90, a PEG ratio of 1.08 and a beta of 0.27. The company has a current ratio of 0.91, a quick ratio of 0.73 and a debt-to-equity ratio of 207.87. The stock has a 50-day moving average of GBX 1,434.78 and a 200 day moving average of GBX 1,404.95.

Insider Activity

In related news, insider Emma Walmsley sold 28,576 shares of the stock in a transaction that occurred on Tuesday, February 14th. The stock was sold at an average price of GBX 1,487 ($18.26), for a total transaction of £424,925.12 ($521,828.71). In related news, insider Emma Walmsley sold 28,576 shares of the company’s stock in a transaction dated Tuesday, February 14th. The shares were sold at an average price of GBX 1,487 ($18.26), for a total transaction of £424,925.12 ($521,828.71). Also, insider Jonathan Symonds acquired 2,100 shares of the firm’s stock in a transaction on Monday, March 20th. The shares were bought at an average cost of GBX 1,399 ($17.18) per share, for a total transaction of £29,379 ($36,078.84). Over the last 90 days, insiders bought 2,117 shares of company stock worth $2,962,765. Insiders own 0.72% of the company’s stock.

GSK Company Profile

(Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider GSK, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and GSK wasn’t on the list.

While GSK currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk’s Next Move

Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Source: marketbeat.com

About the author


Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai